



BY FACSIMILE AND FIRST CLASS MAIL

JAN 28 2002

Jonathan W. Emord, Esq.
Emord & Associates, P.C.
Suite 600
1050 17th Street, N.W.
Washington, D.C. 20036

Re: Health Claim: Omega-3 Fatty Acids and Coronary Heart
Disease (Docket Number 91N-0103)

Dear Mr. Emord:

Reference is made to your request, submitted in a letter to Daniel E. Troy on November 19, 2001, that the Food and Drug Administration (FDA) reconsider its October 31, 2000 decision in the above captioned matter. Specifically, you requested that the agency consider a short disclaimer.

As you are aware from your discussions with the Office of the Chief Counsel, FDA is actively considering your request. Taking into account the availability of staff, and other competing matters, the agency can provide you with the final response on or before February 8, 2002.

Sincerely,

Christine J. Taylor, Ph.D.
Director
Office of Nutritional Products, Labeling
and Dietary Supplements
Center for Food Safety
and Applied Nutrition

cc: Dockets Management Branch (HFA-305)
Daniel E. Troy, Chief Counsel

91N-0103

ANS 1